Clinical trials: Non Valvular Atrial Fibrillation, open to volunteers
Non-valvular Atrial Fibrillation (NVAF), Thromboembolism
Stepwise vs Standard Anticoagulation for AF Patients Undergoing CIED Implantation (STEP-AF)
This is a multi-center, prospective, open-label, randomized controlled trial (STEP-AF) designed to evaluate the safety of a stepwise anticoagulation strategy compared with the guideline-recommended standard anticoagulation…
- Conditions
- Non-valvular Atrial Fibrillation (NVAF), Thromboembolism, Cardiac Implantable Electronic Device, Perioperative Bleeding
- Trial name
- STEP-AF (NCT07616414)
- Testing
- Stepwise Anticoagulation Regimen, Standard Anticoagulation Regimen
- Where
- China
- Volunteers
- 424 people
- Sponsor
- Fu Wai Hospital, Beijing, China
Atrial Fibrillation, Peritoneal Dialysis Complication
Safety and Efficacy of Apixaban Versus Warfarin in Peritoneal Dialysis Patients With Non Valvular Atrial Fibrillation: a Prospective, Randomised, Open-label, Blinded End-point Trial (APIDP2)
Introduction: Several randomised controlled trials have demonstrated that novel oral anticoagulants (NOACs) are safer compared to vitamin K antagonists for the management of non valvular atrial fibrillation (NVAF) to prevent…
- Trial name
- APIDP2 (NCT06045858)
- Testing
- Anticoagulation Agents
- Volunteers
- 178 people
- Sponsor
- University Hospital, Caen
Non-valvular Atrial Fibrillation, Embolic Stroke
Left Atrial Appendage Closure as Secondary Prevention of Atrial Fibrillation-related Embolic Events
This clinical study is a prospective, multi-center, non-interventional study designed to investigate the safety and effectiveness of percutaneous LAA appendage closure by using LAmbre™ Left Atrial Appendage Occluder System.
- Trial name
- NCT04559243
- Testing
- Transthoracic Echocardiography
- Where
- 5 sites in China
- Volunteers
- 579 people
- Sponsor
- Lifetech Scientific (Shenzhen) Co., Ltd.
Atrial Fibrillation (AF), Atrial Fibrillation (Prevention of Stroke)
Stroke Risk Assessment and Markers of Blood Clotting in Patients With Newly Diagnosed Non-valvular Atrial Fibrillation (NVAF), Who Have Not Received Oral Anticoagulation Therapy (OAC-therapy) Prior to Inclusion
Background: Atrial fibrillation (AF) is the most common heart rhythm disorder worldwide. Globally, there are 37.5 million people with AF.
- Conditions
- Atrial Fibrillation (AF), Atrial Fibrillation (Prevention of Stroke), Atrial Fibrillation New Onset, Non Valvular Atrial Fibrillation
- Trial name
- BIO-AF (NCT06949319)
- Where
- Denmark
- Volunteers
- 150 people
- Sponsor
- Nedim Tojaga
Non-valvular Atrial Fibrillation (NVAF): Paroxysmal, Persistent, Permanent
Left Atrial Appendage Closure in Patients With Non-valvular Atrial Fibrillation and End-stage Chronic KIDNEY Disease
In the proposed event driven trial, LAA closure devices will be compared in a 1:1 randomization to best medical care in AF patients at high risk of stroke and bleeding with ESKD.
- Trial name
- LAA-KIDNEY (NCT05204212)
- Testing
- Left Atrial Appendage closure
- Where
- Germany
- Volunteers
- 430 people
- Sponsor
- Prof. Dr. med. Ingo Eitel
Aortic Stenosis Disease, Valvular Heart Disease
Optimized Expansion of the Implanted Transcatheter Aortic Valve
Optimized Expansion of the implanted transcatheter aortic valve to reduce hypoattenuating leaflet thickening in non-atrial fibrillation patients undergoing transcatheter aortic valve implantation (TAVI): an international…
- Trial name
- OptEx-TAVI (NCT07042529)
- Testing
- OptEx-TAVI, SoC-TAVI
- Where
- 17 sites in Belgium, Denmark and 4 more
- Volunteers
- 1,010 people
- Sponsor
- Ole De Backer
Non-valvular Atrial Fibrillation (NVAF), Venous Thromboembolism (VTE)
Precision Antithrombotic Therapy
The goal of this observational study is to systematically analyze the relationship between trough/peak concentrations of novel oral anticoagulants (NOACs) and antiplatelet drugs with clinical events, aiming to provide high-level…
- Conditions
- Non-valvular Atrial Fibrillation (NVAF), Venous Thromboembolism (VTE), MI(Myocardial Infarction), Ischemic Stroke
- Trial name
- NCT07654634
- Testing
- Not applicable- observational study
- Where
- China
- Volunteers
- 5,000 people
- Sponsor
- The Third Xiangya Hospital of Central South University
Non Valvular Atrial Fibrillation
Applause Study I - Append System Early Feasibility Study
This early feasibility study is intended to evaluate the safety and feasibility of the Append System for eliminating the left atrial appendage (LAA) through a transcatheter procedure that invaginates and ligates the LAA tissue.
- Trial name
- Applause (NCT07278869)
- Testing
- Left Atrial Appendage Elimination: Append System
- Where
- 3 sites in United States
- Volunteers
- 15 people
- Sponsor
- Append Medical Ltd.
Atrial Fibrillation
Assessing the Safety and Efficacy of the LAmbre™ Plus Device
Randomized controlled trial assessing the safety and efficacy of the LAmbre Plus LAA Closure System to rescue the risk of thromboembolism in patients with non-valvular AF.
- Trial name
- REDUCE-AF (NCT06465706)
- Testing
- LAmbre investigational device
- Volunteers
- 1,826 people
- Sponsor
- Kansas City Heart Rhythm Research Foundation
Non Valvular Atrial Fibrillation
Apixaban Versus Rivaroxaban in Non Valvular Atrial Fibrillation
The investigators will first measure the maximum concentration (after 2 hours of intake) and the residual concentration (just before the next intake) after at least 15 consecutive days of treatment.
- Trial name
- APIXA-Xa (NCT06862726)
- Testing
- Anti Xa dosage, Dosage of PT-INR
- Where
- Tunisia
- Volunteers
- 120 people
- Sponsor
- Les Laboratoires des Médicaments Stériles
Atrial Fibrillation, Intracardiac Thrombus
Response of Intracardiac Thrombus to Anticoagulants in Patients With Non-valvular Atrial Fibrillation (LYSIS)
This study aims to analyze changes in the immune status, metabolic status, and host microbiome community structure in non-valvular atrial fibrillation patients with intracardiac thrombus.
- Trial name
- LYSIS (NCT06141538)
- Testing
- Observational; No Interventions were given.
- Where
- China
- Volunteers
- 500 people
- Sponsor
- First Affiliated Hospital Xi'an Jiaotong University
Atrial Fibrillation, Antithrombotic Therapy
Dual Antithrombotic Therapy With Dabigatran and Ticagrelor in Patients With ACS and Non-valvular AF Undergoing PCI
More than 25% of patients referred for diagnostic coronary angiography and percutaneous coronary intervention (PCI) due to acute coronary syndrome (ACS) suffer from non-valvular atrial fibrillation (AF).
- Conditions
- Atrial Fibrillation, Antithrombotic Therapy, Acute Coronary Syndrome, Percutaneous Coronary Interventions
- Trial name
- ADONIS-PCI (NCT04695106)
- Testing
- Ticagrelor, Dabigatran Etexilate, Aspirin
- Where
- Poland
- Volunteers
- 1,194 people
- Sponsor
- Medical University of Gdansk
Atrial Fibrillation
Thromboembolic and Bleeding Risk Stratification in Patients With Non-valvular Atrial Fibrillation
The aim of the present prospective study is to further develop and validate a composite risk score predicting both ischemic and bleeding risk, based on epidemiologic, clinical, biological, and/or morphologic complementary data.
- Trial name
- FASTRHAC (NCT02741349)
- Where
- 4 sites in France
- Volunteers
- 825 people
- Sponsor
- Saint Antoine University Hospital
Non Valvular Atrial Fibrillation (nv AF)
Population Pharmacokinetics of Apixaban in Asian Patients With Atrial Fibrillation
The goal of this observational study is to learn about the variability of apixaban blood levels and identify the clinical factors that influence them in Asian patients with atrial fibrillation.
- Trial name
- NCT07747948
- Testing
- Apixaban
- Where
- Thailand
- Volunteers
- 200 people
- Sponsor
- Chulalongkorn University
Non Valvular Atrial Fibrillation
Append Prague Study
This study is intended to evaluate the safety and feasibility of the Append System for left atrial appendage (LAA) elimination using a transcatheter procedure that invaginates and ligates the LAA tissue.
- Trial name
- NCT07816029
- Testing
- Append System
- Where
- Czechia
- Volunteers
- 75 people
- Sponsor
- Append Medical Ltd.
Atrial Fibrillation, Left Atrial Appendage Occlusion
Pulsed Field Ablation for Non-valvular Atrial Fibrillation After Left Atrial Appendage Occlusion
This is a single-center, prospective, single-arm clinical trial designed to evaluate the safety and efficacy of pulsed field ablation (PFA) after left atrial appendage occlusion (LAAO) in patients with non-valvular atrial…
- Conditions
- Atrial Fibrillation, Left Atrial Appendage Occlusion, Pulsed Field Ablation
- Trial name
- PFA after LAAO (NCT07313228)
- Testing
- Pulsed Field Ablation
- Volunteers
- 70 people
- Sponsor
- First Affiliated Hospital of Ningbo University
Atrial Fibrillation
Post-marketing Clinical Study of the LAMBRE System for Left Auricle Closure
Atrial fibrillation (AF) is responsible for 15-20% of ischaemic strokes. These events are often caused by thrombus formation in the left atrium. Thromboembolic risk in AF is primarily prevented by oral anticoagulation.
- Trial name
- ESCALLE (NCT06465459)
- Testing
- LAMBRE device implantation
- Where
- France
- Volunteers
- 220 people
- Sponsor
- French Cardiology Society
Non-valvular Atrial Fibrillation (NVAF)
FIM Study of the LAmbre™ II LAA Occluder in Non-Valvular AF Patients
To evaluate the preliminary safety and feasibility of the LAmbreTM II Left Atrial Appendage Occluder and the Occluder Delivery System in patients with non-valvular atrial fibrillation who are at increased risk for stroke and…
- Trial name
- NCT07385599
- Testing
- LAmbre™ II Left Atrial Appendage Occluder and Occluder Delivery System
- Where
- Hong Kong
- Volunteers
- 10 people
- Sponsor
- Lifetech Scientific (Shenzhen) Co., Ltd.
Atrial Fibrillation
Shared Decision Making to Address Racial Disparities in Oral Anticoagulation in NVAF
The study is a pilot analysis using a decision on the risk and benefits of oral anticoagulation for stroke reduction for patients with non-valvular atrial fibrillation.
- Trial name
- NCT04956978
- Testing
- Patient Decision Support Tool
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Duke University
Non-valvular Atrial Fibrillation (NVAF), High Risk of Stroke
A Prospective, Single-arm Study Evaluating the Endothelialization Effect and Timeline of AnchorMan® Left Atrial Appendage Occluder in Non-valvular Atrial Fibrillation Patients at High Risk of Stroke
This study aims to evaluate the endotheliation efficacy of the AnchorMane® Left Atrial Appendage Occluder in non-valvular atrial fibrillation patients at high stroke risk.
- Trial name
- AnchorMan-NVAF (NCT07396493)
- Testing
- Intra-operative application of LAAC
- Volunteers
- 306 people
- Sponsor
- Shanghai Zhongshan Hospital